For the past few years, neurologists have been successfully using fingolimod (an oral tablet) for people with relapsing-remitting MS. However, because of the adverse effects it can have, such as changes in heart rhythm or eye problems, researchers are looking to find a similar drug that maintains the desired effects but causes less adverse events.
Ozanimod could be the solution to this problem. As the first step toward approving the drug, this international study carried out in fifty five MS centres across Europe and the USA, looked at potential unwanted effects of ozanimod. It also assessed whether ozanimod was safe to be taken by people with relapsing-remitting MS.
The final results were positive, showing improvements in MRI of people with relapsing-remitting MS. The next is to confirm efficacy in a larger phase III trial, which is ongoing.
Read the full article (external website opens in a new window).